These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
687 related articles for article (PubMed ID: 20677923)
1. Fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin (FLAG-IDA) for the treatment of children with poor-prognosis acute leukemia: the Hacettepe experience. Tavil B; Aytac S; Balci YI; Unal S; Kuskonmaz B; Yetgin S; Gurgey A; Tuncer M; Gumruk F; Uckan D; Cetin M Pediatr Hematol Oncol; 2010 Oct; 27(7):517-28. PubMed ID: 20677923 [TBL] [Abstract][Full Text] [Related]
2. [IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF)--an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study]. Fleischhack G; Graf N; Hasan C; Ackermann M; Breu H; Zernikow B; Bode U Klin Padiatr; 1996; 208(4):229-35. PubMed ID: 8926688 [TBL] [Abstract][Full Text] [Related]
3. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of relapsed or poor risk childhood acute leukemia. Yalman N; Sarper N; Devecioğlu O; Anak S; Eryilmaz E; Can M; Yenilmez H; Ağaoğlu L; Gedikoğlu G Turk J Pediatr; 2000; 42(3):198-204. PubMed ID: 11105617 [TBL] [Abstract][Full Text] [Related]
4. FLAG-IDA in the treatment of refractory/relapsed adult acute lymphoblastic leukemia. Specchia G; Pastore D; Carluccio P; Liso A; Mestice A; Rizzi R; Ciuffreda L; Pietrantuono G; Liso V Ann Hematol; 2005 Nov; 84(12):792-5. PubMed ID: 16047203 [TBL] [Abstract][Full Text] [Related]
5. IDA-FLAG regimen for the therapy of primary refractory and relapse acute leukemia: a single-center experience. Yavuz S; Paydas S; Disel U; Sahin B Am J Ther; 2006; 13(5):389-93. PubMed ID: 16988532 [TBL] [Abstract][Full Text] [Related]
6. FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: single-center experience. Pastore D; Specchia G; Carluccio P; Liso A; Mestice A; Rizzi R; Greco G; Buquicchio C; Liso V Ann Hematol; 2003 Apr; 82(4):231-5. PubMed ID: 12707726 [TBL] [Abstract][Full Text] [Related]
7. FLAG-idarubicin and allogeneic stem cell transplantation for Ph-positive ALL beyond first remission. Deane M; Koh M; Foroni L; Galactowicz G; Hoffbrand AV; Lawler M; Secker-Walker L; Prentice HG Bone Marrow Transplant; 1998 Dec; 22(12):1137-43. PubMed ID: 9894715 [TBL] [Abstract][Full Text] [Related]
8. [Effect of modified FLAG regimen therapy on 33 patients with relapsed/refractory leukemia]. Meng FY; Yang LJ; Xu B; Liu XL; Zheng WY; Zhang Y; Huang F; Sun J; Liu QF Ai Zheng; 2003 Dec; 22(12):1330-3. PubMed ID: 14693062 [TBL] [Abstract][Full Text] [Related]
11. FLAG-IDA in the treatment of refractory/relapsed acute leukaemias: single centre study. Hashmi KU; Khan B; Ahmed P; Raza S; Hussain I; Mahmood A; Iqbal H; Malik HS; Anwar M J Pak Med Assoc; 2005 Jun; 55(6):234-8. PubMed ID: 16045091 [TBL] [Abstract][Full Text] [Related]
12. Fludarabine, ARA-C, idarubicin and G-CSF (FLAG-Ida), high dose ARA-C and early stem cell transplant. A feasable and effective therapeutic strategy for de novo AML patients. Clavio M; Gatto S; Beltrami G; Quintino S; Canepa L; Pierri I; Galbusera V; Carrara P; Miglino M; Varaldo R; Ballerini F; Venturino C; Cerri R; Risso M; Balleari E; Carella AM; Sessarego M; Ghio R; Bacigalupo A; Gobbi M J Exp Clin Cancer Res; 2002 Dec; 21(4):481-7. PubMed ID: 12636093 [TBL] [Abstract][Full Text] [Related]
13. [IDA-FLAG regimen in treatment of patients with refractory or relapsed acute leukemia]. Qian SX; Li JY; Wu HX; Zhang R; Hong M; Xu W; Qiu HX Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Apr; 17(2):464-7. PubMed ID: 19379589 [TBL] [Abstract][Full Text] [Related]
14. High remission rate, short remission duration in patients with refractory anemia with excess blasts (RAEB) in transformation (RAEB-t) given acute myelogenous leukemia (AML)-type chemotherapy in combination with granulocyte-CSF (G-CSF). Estey EH; Kantarjian HM; O'Brien S; Kornblau S; Andreeff M; Beran M; Pierce S; Keating M Cytokines Mol Ther; 1995 Mar; 1(1):21-8. PubMed ID: 9384660 [TBL] [Abstract][Full Text] [Related]
15. IDA-FLAG (idarubicin, fludarabine, cytarabine, G-CSF), an effective remission-induction therapy for poor-prognosis AML of childhood prior to allogeneic or autologous bone marrow transplantation: experiences of a phase II trial. Fleischhack G; Hasan C; Graf N; Mann G; Bode U Br J Haematol; 1998 Aug; 102(3):647-55. PubMed ID: 9722289 [TBL] [Abstract][Full Text] [Related]
16. FLAG/FLAG-IDA regimen for children with relapsed/refractory acute leukemia in the era of targeted novel therapies. Mustafa O; Abdalla K; AlAzmi AA; Elimam N; Abrar MB; Jastaniah W J Oncol Pharm Pract; 2019 Dec; 25(8):1831-1838. PubMed ID: 30518307 [TBL] [Abstract][Full Text] [Related]
17. [Effectiveness and safety of the FLAG-IDA regimen in acute refractory or recurrent leukaemia]. Domínguez Senín L; Rodríguez Rodríguez JN; Garrido Martínez MT; Sánchez Argáiz M; Martín Chacón E Farm Hosp; 2012; 36(4):261-7. PubMed ID: 22137611 [TBL] [Abstract][Full Text] [Related]
18. Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia. De Astis E; Clavio M; Raiola AM; Ghiso A; Guolo F; Minetto P; Galaverna F; Miglino M; Di Grazia C; Ballerini F; Marani C; Pastori G; Mitscheunig L; Cruciani F; Lovera D; Varaldo R; Ghiggi C; Lemoli RM; Bacigalupo A; Gobbi M Ann Hematol; 2014 Dec; 93(12):2011-8. PubMed ID: 24989345 [TBL] [Abstract][Full Text] [Related]
19. FLAGIDA-lite is an effective regimen for patients between 70 and 80 years with acute myeloid leukemia or refractory anemia with excess blasts-2 and is feasible as outpatient treatment. Bermúdez A; Pérez-Vázquez G; Insunza A; Baro J; Colorado M; Conde E; Díez-Gallarreta Z; Gutiérrez ML; López-Duarte M; Olalla I; Sanroma P; Yañez L; Iriondo A; Richard C Am J Hematol; 2012 Jan; 87(1):42-4. PubMed ID: 22015963 [TBL] [Abstract][Full Text] [Related]
20. Ponatinib with fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor chemotherapy for patients with blast-phase chronic myeloid leukaemia (MATCHPOINT): a single-arm, multicentre, phase 1/2 trial. Copland M; Slade D; McIlroy G; Horne G; Byrne JL; Rothwell K; Brock K; De Lavallade H; Craddock C; Clark RE; Smith ML; Fletcher R; Bishop R; Milojkovic D; Yap C Lancet Haematol; 2022 Feb; 9(2):e121-e132. PubMed ID: 34906334 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]